What do National Institutes of Health funding cuts mean for universities? We ask Holden Thorp, editor-in-chief of the journal Science and former University of North Carolina at Chapel Hill chancellor.
There's widespread confusion and fear among scientists and doctors on the sprawling National Institutes of Health campus and at institutions dependent on the agency's funding.
Research and basic information on subjects ranging from tuberculosis surveillance to adolescent health disappeared from federal health agency websites.
An email obtained by NPR says NIH employees are subject to a travel freeze and offers of employment are being rescinded. Scientists worry about disruptions to critical research.
Dr. Jay Bhattacharya, a Stanford health researcher, is in line to lead the National Institutes of Health. Early in the pandemic he argued against lockdowns and focusing on people at highest risk.
The federal government has allocated $1.15 billion so far on long COVID research, without bringing any new treatments to market. Patients and scientists say it's time to push harder for breakthroughs.
The National Institutes of Health, the crown jewel of biomedical research in the U.S., could face big changes under the new Trump administration, some fueled by pandemic-era criticisms of the agency.
During the early days of the pandemic, former NIH Director Dr. Francis Collins became a familiar voice steering the country through an unprecedented public health crisis.
Now, he is going through his own health crisis, an aggressive form of prostate cancer. By talking about it publicly he hopes to draw attention to routine screening.
For sponsor-free episodes of Consider This, sign up for Consider This+ via Apple Podcasts or at plus.npr.org.
The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.
The National Institutes of Health initiative that aims to make human genome research more inclusive reports its first results. Some 275 million new genetic variations have been identified.
The National Institutes of Health has been reluctant to use its leverage as a biomedical research funder to influence drug pricing. Sen. Bernie Sanders is pressing NIH's new director to take action.
The Vermont senator held up the nomination process for Dr. Monica Bertagnolli to lead the health agency in order to make a point about drug prices. Now, he says he'll vote against her.